Eisai Company, Ltd.
4-6-10 Koishikawa, Bunkyo-ku
Tokyo
112-8088
United States
Tel: 81-3-3817-3700
Website: http://www.eisai.com/
Email: webmaster@eisai.co.jp
351 articles about Eisai Company, Ltd.
-
Eisai Announces Presentations of Latest Research on Oncology Pipeline at the 110th American Association for Cancer Research (AACR) Annual Meeting
3/29/2019
Six pipeline presentations profile innovative approaches being studied by Eisai and its subsidiary H3 Biomedicine, including data on structurally novel STING agonist
-
H3 Biomedicine Announces Multiple Presentations at Upcoming AACR Annual Meeting
3/25/2019
Presentations highlight company’s expertise seamlessly integrating human biology, data science and modern chemistry to advance a pipeline of investigational breakthrough precision oncology medicines
-
Initiation Of Phase III Clinical Trial Of BAN2401 In Early Alzheimer's Disease
3/22/2019
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer's disease has been initiated. BAN2401 is being jointly developed by Eisai and Biogen Inc.
-
Eisai to Present Latest Research about Alzheimer's Disease/Dementia Pipeline at The 14th International Conference on Alzheimer's & Parkinson's Diseases
3/22/2019
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that seven poster presentations from its Alzheimer's disease/dementia pipeline will be highlighted at the 14th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD) on March 26-31 in Lisbon, Portugal.
-
Global Opinion Leaders from G20 Nations Urge Japanese Prime Minister Shinzo Abe to Establish Aging, Lifelong Brain Health, and Dementia as Central Pillars of G20 Agenda
3/21/2019
Taking proactive steps to maintain healthy aging and overall brain health can delay or even prevent cognitive decline. Global leaders call on Prime Minister Abe to prioritize Alzheimer's and brain health globally at the upcoming G20 summit in Osaka.
-
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease
3/21/2019
Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials
-
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
3/11/2019
A Prescription Drug User Fee Act (PDUFA) date is set for December 27, 2019.
-
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan
3/7/2019
Eisai Co., Ltd. has announced that a marketing authorization application has been submitted in Japan for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for use in the treatment of insomnia disorder.
-
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan
2/27/2019
Contributing Further to Patients With Mycetoma, a Neglected Tropical Disease
-
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
2/21/2019
AbbVie announced that they have received approval for an additional indication of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody, for the treatment of hidradenitis suppurativa.
-
Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy
2/13/2019
Eisai Co., Ltd. announced that it has submitted an application to the European Medicines Agency for its in-house discovered antiepileptic drug Fycompa seeking approval for use in pediatric patients with epilepsy.
-
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study at the Sleep Research Society's Conference: Advances in Sleep and Circadian Science
2/4/2019
Six-month data show significant improvements in patient-reported measures of sleep onset and sleep maintenance for investigational agent lemborexant
-
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time
1/22/2019
Highest Ranked Japanese Company
-
On-Road Driving Safety Study of Investigational Lemborexant Published in SLEEP®
1/22/2019
Lemborexant taken at bedtime had no significant effect on automobile driving performance the next morning in healthy adult and elderly volunteers
-
Eisai to Present Results of Post-Hoc Analyses of Lenvima (Lenvatinib) Phase III Reflect Study in Hepatocellular Carcinoma at 2019 Gastrointestinal Cancers Symposium
1/15/2019
Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting the latest data from post-hoc analyses of a Phase III clinical study (REFLECT/Study 304) on its in-house discovered multiple receptor tyrosine kinase inhibitor lenvatinib mesylate will be presented during the 2019 Gastrointestinal Cancers Symposium (ASCO-GI) in San Francisco from January 17 to 19.
-
Eisai's New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
1/15/2019
Eisai Co., Ltd. and Purdue Pharma L.P. today announced that a new drug application has been submitted to the U.S. Food and Drug Administration (FDA) for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for the treatment of insomnia, a sleep-wake disorder.
-
New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
1/15/2019
Eisai Co., Ltd. and Purdue Pharma, L.P. announced that a new drug application has been submitted to the U.S. Food and Drug Administration (FDA) for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for the treatment of insomnia, a sleep-wake disorder.
-
Eisai's New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration
1/4/2019
For Adjunctive Treatment of Partial Onset Seizures
-
Eisai's Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards
1/4/2019
For Dealing with Viruses and Bacteria! Antimicrobial Barrier that Lasts for 1 Week
-
Eisai: MOVICOL Launched in Japan
11/29/2018
The First Polyethylene Glycol Preparation for Chronic Constipation in Japan